The United States Food and Drug Administration (FDA) on Wednesday approved the Lenkapavir (LEN), which is the most promising HIV prevention medicine to be done so far, and Dr. Guilda, President Emeritus, according to the AIDS Society of India, the real success will be when the lane is accessible, cheap and available to all worldwide.
Lenakpavir is an antiretroviral drug used as an east-exposure Prophylaxis or prep for HIV prevention. Prep is a drug that can reduce the risk of HIV infection for individuals with HIV-negative, but is at risk of contracting the virus. The results of two major studies have shown that it helps prevent 99.9 percent of all HIV transmission.
Chairman of AIDS Society of India (ASI) Dr. Glory Alexander said, “Lane is an injectable prep that is to be taken twice annually.”
Prep was first approved by the US FDA in 2012, but the National AIDS Control Organization of the Government of India has yet to roll it out. “If we invest in the prevention of HIV, we not only protect people’s health, but also protect expenses in providing lifetime HIV care, including lifelong antiretroviral therapy (ART). HIV prevention should remain in the center of our national AIDS response,” Dr. Gilda said.
“Indian regulators should work with Indian generic manufacturing companies to ensure that ‘generic lane versions made in India are available, the first is rolled out in India.”
“Scientific success is transformed into public health effects in terms of preventing the spread of HIV infection. The major hurdle is the cost: the lane is sold as Yezto as a prep sold as a lane. Dr. Gilada explained.
Dr. Gilda said, “India needs to lead the front to prevent HIV transmission and help AIDS on the required scale on the necessary and timely distribution,” Dr. Gilada said, India can only distribute all those around the world, which is in terms of quality, quantity and speed.
The story continues below this advertisement
Although India fulfills 92 percent of the global requirement for art and global community (Joe, UNEDs, Global Fund, World Bank, etc.), widely uses Indian generic pharma for its strategies such as prevention (TASP) (TASP) (TASP) (TASP) (TASP) (TASP) (TASP) (TASP) (TASP), Testing and Testing, Post-Ec-Exposure Profilaxis (PEP), PREP, PREP, etc. Are.
Gilead faced a lot of backlash from health advocates and communities on astronomical pricing for Len last year, assuming over $ 40,000 per person per year, which has now been dropped to 30 percent.
Earlier, the hepatitis C treatment of the gilid, which was costing $ 84,000 in the US for a three -month course, was provided for less than $ 300 in India. So the firm knew what to do this time, and six generic manufacturers including four Indians were given voluntary licensing: Dr. Reddy’s laboratories, Emkur, Hatero Healthcare and Viatris.
“All international antiretroviral therapy and prevention are applied to the concept and strength of India. Only India can meet the global demand for lanes at such a low cost, as it was for art, which was 0.3 percent of the cost of the nephew,” Dr. Gilda said.
,
